MAIA

Maia Biotechnology Inc

Add to Watchlist

Advanced Chart

1.520

+0.04(2.703%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.530

Open

1.470

VWAP

1.50

Vol

89.52K

Mkt Cap

46.07M

Low

1.4601

Amount

134.20K

EV/EBITDA(TTM)

Total Shares

21.84M

35.20M

EV/OCF(TTM)

P/S(TTM)

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.250

-37.5%

-0.190

+72.73%

-0.130

-34.06%

Estimates Revision

Stock Price

Go Down

-20.83%

In Past 3 Month

1 Analyst Rating

821.05% Upside

Wall Street analysts forecast MAIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAIA is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

821.05% Upside

Current: 1.520

Low

14.00

Averages

14.00

High

14.00

821.05% Upside

Current: 1.520

Low

14.00

Averages

14.00

High

14.00

The End

See All Ratings

No Data

Valuation Metrics

The current forward P/E ratio for Maia Biotechnology Inc (MAIA.A) is -2.03, compared to its 5-year average forward P/E of -1.44. For a more detailed relative valuation and DCF analysis to assess Maia Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.44

Current PE

-2.03

Overvalued PE

-0.48

Undervalued PE

-2.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.32

Current EV/EBITDA

-1.19

Overvalued EV/EBITDA

-0.77

Undervalued EV/EBITDA

-1.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.57

Current PS

0.00

Overvalued PS

4.98

Undervalued PS

-1.84